First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from asco 2008

Sunitinib is now a standard first-line therapy for metastatic clear-cell kidney cancer. This paper focuses on interpretation of the overall survival data presented at the 2008 annual meeting of the American Society of Clinical Oncology from the pivotal phase iii trial comparing sunitinib with interf...

Descripción completa

Detalles Bibliográficos
Autor principal: Wood, L.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2009
Materias:
Urologic Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687808/
https://www.ncbi.nlm.nih.gov/pubmed/19478904
_version_ 1782167597514489856
author Wood, L.
author_facet Wood, L.
author_sort Wood, L.
collection PubMed
description Sunitinib is now a standard first-line therapy for metastatic clear-cell kidney cancer. This paper focuses on interpretation of the overall survival data presented at the 2008 annual meeting of the American Society of Clinical Oncology from the pivotal phase iii trial comparing sunitinib with interferon in the first-line setting. The previously published progression-free survival and response rate data from that study are also summarized.
format Text
id pubmed-2687808
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Multimed Inc.
record_format MEDLINE/PubMed
spelling pubmed-26878082009-05-28 First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from asco 2008 Wood, L. Curr Oncol Urologic Oncology Sunitinib is now a standard first-line therapy for metastatic clear-cell kidney cancer. This paper focuses on interpretation of the overall survival data presented at the 2008 annual meeting of the American Society of Clinical Oncology from the pivotal phase iii trial comparing sunitinib with interferon in the first-line setting. The previously published progression-free survival and response rate data from that study are also summarized. Multimed Inc. 2009-05 /pmc/articles/PMC2687808/ /pubmed/19478904 Text en 2009 Multimed Inc. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Urologic Oncology
Wood, L.
First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from asco 2008
title First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from asco 2008
title_full First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from asco 2008
title_fullStr First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from asco 2008
title_full_unstemmed First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from asco 2008
title_short First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from asco 2008
title_sort first-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from asco 2008
topic Urologic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687808/
https://www.ncbi.nlm.nih.gov/pubmed/19478904
work_keys_str_mv AT woodl firstlinetherapywithsunitinibinadvancedrenalcellcarcinomainterpretationoftheoverallsurvivaldatafromasco2008

Ejemplares similares